Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives

References

• UNAIDS. 2006 Report on the global AIDS epidemic: A UNAIDS 10th anniversary special edition, 2006.
   Google Scholar
• Massad L S, Springer G, Jacobson L, et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. Aids 2004; 18: 281–286
   PubMed Web of Science ®Google Scholar
• van Benthem B H, de Vincenzi I, Delmas M C, et al. Pregnancies before and after HIV diagnosis in a European cohort of HIV-infected women. European Study on the Natural History of HIV Infection in Women. Aids 2000; 14: 2171–2178
   PubMed Web of Science ®Google Scholar
• Finer L B, Henshaw S K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38: 90–96
   PubMed Web of Science ®Google Scholar
• http://www.aidsinfo.nih.gov/guidelines/adult/AA_100606.pdf. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, US Department of Health and Human Services; Accessed 10 October 2006, p. 35
   Google Scholar
• Speroff L DP. A clinical guide to contraception. Lippincott, Williams, & Wilkins, Philadelphia, PA 2001
   Google Scholar
• Hatcher R, Trussell J, Stewart F, et al. Contraceptive technology. Ardent Media Inc., New York, NY 2004
   Google Scholar
• Brunton L, Lazo J S, Parker K L. Goodman and Gillman's pharmacological basis of therapeutics. McGraw-Hill Publishing, New York, NY 2005
   Google Scholar
• Cavallari L, Ellingrod V L, Kolesar J M. Lexi-Comp's pharmacogenomics handbook. Lexi-Comp Inc., Hudson, OH 2005
   Google Scholar
• Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194–209
   PubMed Web of Science ®Google Scholar
• Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289–304
   PubMed Web of Science ®Google Scholar
• Lee C G, Gottesman M M, Cardarelli C O, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594–3601
   PubMed Web of Science ®Google Scholar
• Washington C B, Duran G E, Man M C, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 203–209
   PubMedGoogle Scholar
• Cohn S, Watts D, Lertora J, et al. An open-label, non-randomized study of the effect of depo-medroxyprogesterone acetate on the pharmacokinetics (PK) of selected protease inhibitors and non-nucleoside reverse transcriptase inhibitors therapies among HIV-infected women. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 22–252005, Abstract 82
   Google Scholar
• Cohn S E, Park J G, Watts D H, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: Effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81: 222–227
   PubMed Web of Science ®Google Scholar
• Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002; 29: 471–477
   PubMed Web of Science ®Google Scholar
• Laboratories A. Norvir (ritonavir) package insert. North Chicago, IL 2006
   Google Scholar
• Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46: 111–116
   PubMed Web of Science ®Google Scholar
• Frohlich M, Burhenne J, Martin-Facklam M, et al. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004; 57: 244–252
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Lexiva (fosamprenavir) package insert. Research Triangle Park, NC 2004
   Google Scholar
• GlaxoSmithKline. Agenerase (amprenavir) package insert. Research Triangle Park, NC 2004
   Google Scholar
• Tackett D, Child M, Argawala S, et al. Atazanavir: A summary of two pharmacokinetic drug interaction studies in healthy subjects. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 10–142003
   Google Scholar
• Squibb B M. Reyataz (atazanavir) product package insert. Princeton, NJ 2006
   Google Scholar
• Squibb B M. Sustiva (efavirenz) product package insert. Princeton, NJ
   Google Scholar
• Joshi A, Fiske W, Benedek I, et al. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February, 1–51998, Abstract 348
   Google Scholar
• Company M. Crixivan (indinavir) package insert. Whitehouse Station, NC 2003
   Google Scholar
• Laboratories A. Kaletra (lopinavir/ritonavir) package insert. North Chicago, IL 2004
   Google Scholar
• Pharmaceuticals P. Selzentry (maraviroc) package insert. New York, NY 2007
   Google Scholar
• Pharmaceuticals A. Viracept (nelfinavir) package insert. La Jolla, CA 2003
   Google Scholar
• Pharmaceuticals G. Viread (tenofovir) product package insert.
   Google Scholar
• Back D J, Burger D M, Flexner C W, et al. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: Implications for once-daily dosing. J Acquir Immune Defic Syndr 2005; 39(Suppl. 1)S1–23, quiz S24–25
   PubMed Web of Science ®Google Scholar
• Ingelheim B. Aptivus (tipranavir) product package insert.
   Google Scholar
• Tibotec. Prezista (darunavir) product package insert.
   Google Scholar
• World Health Organization. Chronic HIV Care with ARV Therapy and Prevention. July 2006. Available at: http://www.who.int/3by5/publications/documents/chronCareModGenDraftRev1.pdf. Accessed 20 August 2007
   Google Scholar
• Wilson T E, Koenig L J, Walter E, et al. Dual contraceptive method use for pregnancy and disease prevention among HIV-infected and HIV-uninfected women: The importance of an event-level focus for promoting safer sexual behaviors. Sex Transm Dis 2003; 30: 809–812
   PubMed Web of Science ®Google Scholar
• Wilson T E, Koenig L, Ickovics J, et al. Contraception use, family planning, and unprotected sex: Few differences among HIV-infected and uninfected postpartum women in four US states. J Acquir Immune Defic Syndr 2003; 33: 608–613
   PubMed Web of Science ®Google Scholar